Pre-ASCO Watch List #2: ARIA, IMGN, PCYC

http://ezeta.com/index.php?option=com_content buy accutane amazon Rayno Life Science Focus Stocks: ARIA, buy pfizer Lyrica online IMGN, PCYC 

Ariad (ARIA) Abstracts

Several data presentations will be made for Iclusig (Ponatinib)  for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2.

Immunogen (IMGN) Abstracts

The focus will be on two products using ADC (antibody-drug conjugate ) technology: IMGN853 utilizing a folate-receptor alpha targeting antibody in a pharmacokinetics (PK) and clinical evidence study study for epithelial  ovarian cancer (EOC) and solid tumors; and IMGN529 which contains a CD-37 targeting antibody in a dose finding Phase I study for treatment of NHL.

Pharmacyclics (PCYC) Abstracts

A initial Phase 3 study of IMBRUVICA as a single agent for CLL showing long term safety and efficacy and in combination with antibody targeting CD-20 in a Phase 1b/2 study.

————-

Other oncology stocks to watch: AGIO, CELG, CLVS, EPZM, MDVN, PBYI, SGEN, XLRN

ASCO ’14 Preview from Adam Feuerstein: ABBV, GILD, PCYC.

Three Month Stock Performance ARIA, CLDX, IMGN, PCYC with IBB at $231.50, FBT at $75.71

Chart forAriad Pharmaceuticals Inc. (ARIA)

 

 

, , ,

No comments yet.

Leave a Reply